Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
|Videos|June 1, 2013
Dr. Carvajal Describes MEK Inhibition in Uveal Melanoma
Author(s)Richard D. Carvajal, MD
Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition in patients with advanced uveal melanoma using the agent selumetinib.
Advertisement
Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition using the agent selumetinib in patients with advanced uveal melanoma.
The trial exploring selumetinib was the first to discover an effective agent for patients with advanced uveal melanoma. Even though the MEK inhibitor trametinib was recently approved, Carvajal believes clinical trials are still the most appropriate area for treatment with MEK inhibitors in uveal melanoma.
<<<
Advertisement
Related to this article
The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.
Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.
Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.
A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.
Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.
Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC
5